https://www.selleckchem.com/products/dmx-5084.html
Therapeutic drug monitoring (TDM) of anti-tumor necrosis factor agents (anti-TNFs) has received extensive attention due to its potential for improving treatment outcomes in patients with inflammatory bowel diseases. However, the benefits of applying TDM in clinical practice remain largely unclear due to a lack of evidence from the available prospective randomized controlled studies. The questionable evidence for TDM obtained in these studies can be caused by several design suboptimalities, including long turnaround times of sample anal
Like
Comment
Share